Organic sales and order intake grew strongly in Q2 2026, with profitability and cash flow significantly improved by operational gains and a major tariff refund. Acute Care Therapies and Life Science segments led growth, while APAC lagged. Outlook for 2026 remains positive despite ongoing geopolitical and pharma sector uncertainties.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.